Ampio Pharmaceuticals Inc (NYSEAMERICAN:AMPE) saw strong trading volume on Tuesday . 2,913,781 shares were traded during trading, an increase of 110% from the previous session’s volume of 1,387,726 shares.The stock last traded at $3.29 and had previously closed at $3.07.

The firm has a market cap of $188.97, a P/E ratio of -17.00 and a beta of 0.20.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC lifted its holdings in shares of Ampio Pharmaceuticals by 101.9% during the 4th quarter. Geode Capital Management LLC now owns 487,410 shares of the specialty pharmaceutical company’s stock valued at $1,983,000 after acquiring an additional 246,040 shares in the last quarter. Virtu Financial LLC lifted its holdings in shares of Ampio Pharmaceuticals by 787.5% during the 4th quarter. Virtu Financial LLC now owns 92,344 shares of the specialty pharmaceutical company’s stock valued at $376,000 after acquiring an additional 81,939 shares in the last quarter. Carnick & Kubik Group LLC lifted its holdings in shares of Ampio Pharmaceuticals by 46.2% during the 4th quarter. Carnick & Kubik Group LLC now owns 205,481 shares of the specialty pharmaceutical company’s stock valued at $836,000 after acquiring an additional 64,914 shares in the last quarter. Brandes Investment Partners LP acquired a new position in shares of Ampio Pharmaceuticals during the 4th quarter valued at $204,000. Finally, Cypress Capital Management LLC WY lifted its holdings in shares of Ampio Pharmaceuticals by 50.6% during the 4th quarter. Cypress Capital Management LLC WY now owns 108,400 shares of the specialty pharmaceutical company’s stock valued at $441,000 after acquiring an additional 36,400 shares in the last quarter.

ILLEGAL ACTIVITY WARNING: This story was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://www.thecerbatgem.com/2018/02/13/ampio-pharmaceuticals-ampe-sees-strong-trading-volume.html.

About Ampio Pharmaceuticals

Ampio Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused primarily on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. The Company’s two lead product candidates in development are Ampion for osteoarthritis of the knee and Optina for diabetic macular edema.

Receive News & Ratings for Ampio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.